XML 28 R15.htm IDEA: XBRL DOCUMENT v2.4.0.8
The Company and Summary of Significant Accounting Policies (Details)
3 Months Ended 6 Months Ended 12 Months Ended 290 Months Ended 6 Months Ended 12 Months Ended 3 Months Ended
Jun. 30, 2014
EUR (€)
Jun. 30, 2013
EUR (€)
Jun. 30, 2014
USD ($)
Jun. 30, 2014
EUR (€)
Jun. 30, 2013
EUR (€)
Dec. 31, 2013
USD ($)
Jun. 30, 2014
EUR (€)
Dec. 31, 2013
EUR (€)
Jun. 30, 2014
Accounts Receivable [Member]
Dec. 31, 2003
Accounts Receivable [Member]
Jun. 30, 2014
Convertible Loans [Member]
Jun. 30, 2013
Convertible Loans [Member]
Jun. 30, 2013
Warrants [Member]
Jun. 30, 2014
Stock Options [Member]
Jun. 30, 2013
Stock Options [Member]
BASIS OF PRESENTATION [Abstract]                              
Deficit accumulated during the development stage € 65,887,000     € 65,887,000     € 65,887,000 € 64,165,000              
Amount of current liabilities exceed its current assets 37,605,000     37,605,000     37,605,000                
REVENUE RECOGNITION [Abstract]                              
Period to earn royalty payments after first commercial sale     10 years 10 years                      
Upfront fee for license received 0 0 5,000,000 0 0   4,381,000                
Milestone payments received     62,000,000                        
PROPERTY AND EQUIPMENT [Abstract]                              
Estimated useful lives     3 years 3 years                      
Contingent Consideration [Abstract]                              
Issuance of shares to settle continent liability (in shares) 5,338,809   5,338,809 5,338,809     5,338,809                
TAXES ON INCOME [Abstract]                              
Income tax contingency open tax years     December 31, 2009 to 2013 December 31, 2009 to 2013                      
EARNINGS PER SHARE [Abstract]                              
Weighted average number of shares (in shares) 303,112,271 295,318,813 300,778,508 300,778,508 295,318,813                    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]                              
Total potential number of shares issuable (in shares) 486,606,984 447,934,383                 465,756,984 399,418,541 44,940,842 20,850,000 3,575,000
PREFERRED STOCK [Abstract]                              
Preferred stock, shares authorized (in shares) 5,000,000   5,000,000 5,000,000     5,000,000 5,000,000              
Preferred stock, shares issued (in shares) 0   0 0     0 0              
Preferred stock, shares outstanding (in shares) 0   0 0     0 0              
STOCK-BASED COMPENSATION [Abstract]                              
Shares issued to individuals as fee for services rendered (in shares)     0 0 0                    
Incentive stock options awarded (in shares)           20,600,000                  
Exercise price of shares granted (in dollars per share)           $ 0.02                  
Shares vested (in shares)               3,300,000              
Shares exercised (in shares)           3,100,000                  
Number shares of unvested common stock (in shares)               17,300,000              
Vesting period of stock options           4 years                  
Stock based compensation expense 28,000 2,000   56,000 3,000                    
Concentration Risk [Line Items]                              
Concentration percentage                 80.00% 98.00%          
RELATED PARTY TRANSACTIONS [Abstract]                              
Professional fees to counsel's law firm € 10,000 € 23,000   € 25,000 € 86,000